Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics

Core Viewpoint - Bristol Myers Squibb (BMY) is expected to report a significant increase in quarterly earnings per share, while revenues are projected to decline year-over-year [1]. Financial Projections - Analysts predict quarterly earnings of $1.54 per share, reflecting a 135$10.74 billion, representing a year-over-year decrease of 9.5% [1]. - The consensus EPS estimate has been adjusted upward by 0.8% over the past 30 days, indicating a reassessment of initial projections by analysts [2]. Key Metrics Estimates - Net Sales for Recent LOE Products - Revlimid is estimated at $879.35 million, indicating a change of -47.3$2.18 billion, reflecting a year-over-year change of +4.9% [5]. - Net Sales for Recent LOE Products - Abraxane is projected at $127.62 million, showing a change of -41.2$483.40 million, indicating a change of +36.6% year-over-year [6]. - Net Sales for Recent LOE Products - Abraxane (U.S.) is expected to be $66.33 million, reflecting a year-over-year change of -54.3$1.19 billion, indicating a year-over-year change of +3.4% [7]. - Net Sales for In-Line Products - Pomalyst/Imnovid (U.S.) is expected to reach $582.15 million, reflecting a change of -2.5$706.32 million, indicating a change of -51.4% from the prior-year quarter [9]. - Net Sales for New Product Portfolio - Reblozyl (U.S.) is projected at $392.41 million, reflecting a change of +33.9% from the prior-year quarter [10]. Market Performance - Over the past month, Bristol Myers shares have recorded returns of -18.5%, compared to the Zacks S&P 500 composite's -6.9% change [10]. - Based on its Zacks Rank 3 (Hold), BMY is expected to perform in line with the overall market in the upcoming period [10].